Previous 10 | Next 10 |
RedHill and Kukbo Enter Oral Opaganib License for COVID-19 in South Korea RedHill to receive $1.5 million upfront and is eligible for up to $5.6 million in milestone payments in addition to royalties on net sales from Kukbo Opaganib's Phase 2/3 clinical data shows improved v...
RedHill Biopharma to Host Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights Webcast on March 17, 2022 PR Newswire TEL AVIV, Israel and RALEIGH, NC , March 10, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ...
RedHill Biopharma's (NASDAQ:RDHL) oral COVID-19 treatment RHB-107 (upamostat) demonstrated a significant reduction in new severe symptoms in non-hospitalized, symptomatic COVID patients in a phase 2 study. In the study, no patients on RHB-107 were hospitalized, compared to 15% on placebo...
RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19 Phase 2 part of Phase 2/3 study of once-daily oral RHB-107 in symptomatic COVID-19 successfully met the study's primary endpoint showing good safety and tolerability and highly promis...
RedHill Biopharma (RDHL -1.7%) expects Q4 total net revenues to be in the range of $22M to-24M, below the consensus revenue estimate of $24.09M, according to preliminary data. The company had recorded $21.5M in revenue in Q4 2020. RedHill expects to have achieved commercial operations br...
RedHill Biopharma Announces Record Quarterly Revenues and First Commercial Operations Breakeven Business update (unaudited and preliminary estimated fourth quarter financial data[1]): - Record Q4/2021 total net revenues estimated to be in the range of $22-24 million vs. $21....
Announcing data from a Phase 2/3 trial for its COVID-19 therapy opaganib, RedHill Biopharma (RDHL -2.4%) said Monday that the oral treatment “significantly reduced” death among hospitalized patients who had previously received standard-of-care (SOC). According to the prespecifie...
RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19 Updates on Regulatory Discussions and Plans in Multiple Countries Prespecified analysis of Phase 2/3 opaganib data in severe COVID-19 patients showed ...
Even though the stock market is trading lower, there are still plenty of opportunities to make money. You just need to know where to look. What some retail traders are doing right now is looking for hype and popularity on social media. There are multiple ways to find the most active ...
RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients PR Newswire - In a prespecified analysis of all Phase 2/3 study patients with positive PCR at screening, opaganib improved the med...
News, Short Squeeze, Breakout and More Instantly...
Redhill Biopharma Ltd. Company Name:
RDHL Stock Symbol:
NASDAQ Market:
Redhill Biopharma Ltd. Website:
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 22, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biophar...
RedHill Biopharma Terminates License Agreement for Aemcolo® PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 9, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today ...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...